Relationship between maternal prepregnancy fat mass (kg) and exhaled nitric oxide and lung function in the offspring at age 6 years
| Unadjusted analysis | Model 1 | Model 2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta | (95% CI) | p Value | n | β | (95% CI) | p Value | n | β | (95% CI) | p Value | n | |
| FEV1 z-score | 0.0349 | (−0.0413 to 0.1111) | 0.37 | 793 | 0.0274 | (−0.0476 to 0.1025) | 0.47 | 793 | 0.0230 | (−0.0555 to 0.1015) | 0.56 | 784 |
| FVC z-score | 0.0433 | (−0.0439 to 0.1306) | 0.33 | 793 | 0.0301 | (−0.0586 to 0.1188) | 0.5 | 765 | 0.0301 | (−0.0586 to 0.1188) | 0.5 | 765 |
| FEF25–75% z-score | 0.0163 | (−0.0796 to 0.1122) | 0.74 | 793 | 0.0181 | (−0.0775 to 0.1137) | 0.71 | 793 | 0.0071 | (−0.0886 to 0.1028) | 0.88 | 793 |
| FEV1/FVC z-score | −0.0190 | (−0.1043 to 0.0663) | 0.66 | 793 | −0.0130 | (−0.0998 to 0.0739) | 0.77 | 765 | −0.0130 | (−0.0998 to 0.0739) | 0.77 | 765 |
| Exhaled nitric oxide | −0.0575 | (−0.1667 to 0.0517) | 0.30 | 482 | −0.0908 | (−0.2018 to 0.0203) | 0.11 | 477 | −0.0908 | (−0.2018 to 0.0203) | 0.11 | 477 |
| Model 3 | Model 4 | |||||||||||
| FEV1 z-score | 0.0115 | (−0.0702 to 0.0932) | 0.78 | 721 | 0.0122 | (−0.0684 to 0.0928) | 0.76 | 784 | ||||
| FVC z-score | 0.0287 | (−0.0625 to 0.1199) | 0.54 | 713 | 0.0001 | (−0.0913 to 0.0916) | 0.99 | 765 | ||||
| FEF25–75% z-score | −0.0035 | (−0.1031 to 0.0961) | 0.94 | 725 | 0.0160 | (−0.0829 to 0.1149) | 0.75 | 793 | ||||
| FEV1/FVC z-score | −0.0293 | (−0.1181 to 0.0594) | 0.51 | 713 | 0.0055 | (−0.0846 to 0.0956) | 0.9 | 765 | ||||
| Exhaled nitric oxide | −0.0989 | (−0.2152 to 0.0174) | 0.09 | 434 | −0.0889 | (−0.2029 to 0.0250) | 0.12 | 477 | ||||
Regression coefficient represents change in outcome per 10 kg of maternal prepregnancy fat mass.
Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child's birth weight and gestation.
FEV1-child's gender; FVC-maternal smoking in pregnancy and rhinitis, and child's gender; FEF25–75%-maternal parity and child's gender; FEV1/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.
Model 2 adjusted for potential confounders significantly associated with the outcome, including child's birth weight and gestation.
FEV1-maternal height, and child's gender and birth weight; FVC-maternal smoking in pregnancy and rhinitis, and child's gender; FEF25–75%-maternal parity and child's gender and gestation; FEV1/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.
Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome including child's birth weight and gestation (listed in Model 2).
Model 4 adjusted for child's BMI at age 6 years and potential confounders significantly associated with the outcome including child's birth weight and gestation (listed in Model 2).
BMI, body mass index.